Is Lyell Immunopharma, Inc. (LYEL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 12.4% / 30% | 77.7% / 30% | 0.0% / 30% | 39455.74% / 5% | ✗ NOT HALAL |
| DJIM | 12.4% / 33% | 77.7% / 33% | 0.0% / 33% | 39455.74% / 5% | ✗ NOT HALAL |
| MSCI | 12.0% / 33% | 75.5% / 33% | 0.0% / 33% | 39455.74% / 5% | ✗ NOT HALAL |
| S&P | 12.4% / 33% | 77.7% / 33% | 0.0% / 33% | 39455.74% / 5% | ✗ NOT HALAL |
| FTSE | 12.0% / 33% | 75.5% / 33% | 0.0% / 50% | 39455.74% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -1024633.3% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -87.0% | |
| Return on Assets (ROA) | -29.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$150M |
| Free Cash Flow | -$151M |
| Total Debt | $51M |
| Debt-to-Equity | 20.5 |
| Current Ratio | 5.3 |
| Total Assets | $340M |
Price & Trading
| Last Close | $20.22 |
| 50-Day MA | $23.18 |
| 200-Day MA | $18.36 |
| Avg Volume | 110K |
| Beta | -0.1 |
|
52-Week Range
$7.65
| |
About Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Lyell Immunopharma, Inc. (LYEL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Lyell Immunopharma, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Lyell Immunopharma, Inc.'s debt ratio?
Lyell Immunopharma, Inc.'s debt ratio is 12.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 12.0%.
What are Lyell Immunopharma, Inc.'s key financial metrics?
Lyell Immunopharma, Inc. has a market capitalization of $458M, and revenue of $36,000. Return on equity stands at -87.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.